Thursday, July 07, 2022 9:07:22 AM
https://www.businesswire.com/news/home/20220706005843/en/DiaMedica-Therapeutics-Announces-Clinical-Hold-of-its-Phase-23-ReMEDy2-Clinical-Trial-for-DM199
OAN: The announcement today of the start of Algernon's DMT stroke study would appear to be a distraction from the still awaited IPF/Chronic Cough Topline data readout. My best guess is the results will be underwhelming. Thus, you're thrown a piece of red meat to push your mind further down the road. If you're told a study will start in one particular quarter, add a couple more quarters to the story and hold onto your @ss.
On with the show this is it.
M$
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM